ArticleMetabolic brain disease2021
Agomelatine confers neuroprotection against cisplatin-induced hippocampal neurotoxicity.
Article in Metabolic brain disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Investigation of the Effects of Agomelatine in Rats with Experimental Cerebral Ischemia/Reperfusion Model.Biomedicines · 2026Article
- Mechanistic insights and therapeutic interventions of mitochondrial quality control in chemotherapy-related cognitive impairment.Neoplasia (New York, N.Y.) · 2026Review
- Elucidating the mechanism of traditional Chinese medicine formula (Journal of traditional and complementary medicine · 2026Article
- Assessing the role of drug interventions in the polycystic ovary syndrome model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Fluoxetine and agomelatine mitigate anhedonic and hepatic changes in chronic restraint stress rat model.Scientific reports · 2025Article
- The Neuroprotective Impact of Agomelatine in Preserving Brain Tissue Molecular Structure Against Alzheimer's Disease Etiology.Neurochemical research · 2025Article
- Comparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo.Molecular biology reports · 2025Article
- Article
- Cadmium-induced lung injury is associated with oxidative stress, apoptosis, and altered SIRT1 and Nrf2/HO-1 signaling; protective role of the melatonin agonist agomelatine.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Activation of S1PCell proliferation · 2024Article
- Agomelatine on cisplatin-induced nephrotoxicity via oxidative stress and apoptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders.Brain sciences · 2023Review
- Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease.Neural regeneration research · 2023Review
- Tempol improves optic nerve histopathology and ultrastructures in cisplatin-induced optic neuropathy in rats by targeting oxidative stress-Endoplasmic reticulum stress-Autophagy signaling pathways.Frontiers in cellular neuroscience · 2023Article
- Brain Protection by Methylene Blue and Its Derivative, Azur B, via Activation of the Nrf2/ARE Pathway in Cisplatin-Induced Cognitive Impairment.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Metabolic Impact of Anticancer Drugs PdPharmaceutics · 2022Article
- Melatonin ameliorates cisplatin-induced neurodegeneration in medulla oblongata through the expressions of Aqp-1,-4, inflammation, and apoptosis pathway genes.Turkish journal of biology = Turk biyoloji dergisi · 2022Article
- Neuroprotective Potential of Bone Marrow-Derived Mesenchymal Stem Cells Following Chemotherapy.Biomedicines · 2021Article
- The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotoxicity caused by cisplatin is a major obstacle during chemotherapy. Oxidative stress and inflammation are considered the primary mechanism behind neuronal damage which affects the continuing chemotherapy regimen. Agomelatine was recently described as a neuroprotective compound against toxic insults in the nervous systems. It is an analog of the well-known antioxidant and anti-inflammatory compound melatonin and currently used for depression and sleep disturbances. In the current study, we investigated the possible neuroprotective role of agomelatine against cisplatin-induced oxidative, inflammatory, and behavioral alterations in male rats. Our results show that agomelatine prevented cisplatin-induced neurotoxicity in the HT-22 mouse hippocampal neuronal cell line. Additionally, agomelatine treatment inhibited cisplatin-induced behavioral deficits and neuronal integrity in vivo. For the evaluation of the effect of agomelatine on oxidative stress and inflammation, GSH, MDA, TNF, and IL-6 levels were analyzed in HT-22 cells and hippocampal tissues. Agomelatine significantly attenuated oxidative stress and inflammation due to the cisplatin insult in vitro and in vivo. Also, agomelatine treatment ameliorated the neuronal pathology in the hippocampus, which is strongly related to cognition and memory. Taken together, our results indicate that in males, the neuroprotective effect of agomelatine is mediated through its antioxidant and anti-inflammatory actions abrogating functional deficits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.